British testing firm DnaNudge announced on Wednesday that it has partnered with Pantonic Health to launch its CovidNudge test in Australia.

Diagnostics manufacturer Quidel reported after the close of the market on Thursday that its fourth quarter revenues fell more than 21 percent year over year due primarily to shift in product mix and decreased COVID-19 product sales.

Recently, Hong Kong has been hit by the epidemic continuously. On February 16, Kang Keren, senior vice president of Wondfo Biotech, said that in response to the epidemic in Hong Kong, Wondfo's "Anti-epidemic pioneer" is preparing to go to the front line and guarantee supply.

Hologic reported after the close of the market on Wednesday that revenues for its first quarter of fiscal year 2022 decreased 9 percent year over year, driven by lower sales of COVID-19 assays.

Danaher reported on Thursday a 21 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. For the three months ended Dec. 31, conglomerate posted $8.15 billion in total sales compared to $6.76 billion in the year-ago period. The analysts' average estimate was $7.92 billion.

iHealth announced that it was disclosed in the previous announcement that the U.S. subsidiary of the company and the ACC of U.S. signed a purchase contract on ihealth coronavirus antigen home self-test OTC kit products on behalf of HHS, purchasing a total of 250 million iHealth kit products.

Abbott reported Wednesday morning that its fourth quarter diagnostics revenues rose 3 percent year over year, largely as a result of rapid COVID-19 testing.

GE's healthcare systems organic revenues in the fourth quarter declined 5%, more than offsetting 2% organic growth in pharmaceutical diagnostics. Nonetheless, Culp told investors that healthcare order demand remained strong in the quarter despite supply chain disruptions.

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant’s high rate of infection.

Ginkgo Bioworks said on Wednesday that it has acquired Project Beacon COVID-19, a Boston-based coronavirus testing organization.